Next week, the organization will be up on Capitol Hill to testify before the House Energy and Commerce Committee as it further investigates the drug compounding industry.
Last fall, a fungal meningitis contamination at one pharmacy in New England ended up killing 50 people and sickening more than 700.
In March, the NCPA’s chief executive, B. Douglas Hoey, called the New England Compounding Center a “rogue entity” and stressed that the industry is already subject to many state and federal laws and regulations.
“As a country, we must strike the right balance to go after rogue entities like NECC while preserving patients’ access to the safe and essential compounded medications that their physicians prescribe,” Hoey said, pledging that the organization would “continue to work with health officials” on the issue.
—This post was updated at 9:21 p.m.